Menu

Impact Events

More
Date Lead Company Event Type Approval Change Approval Likelihood
10/6/25 Skye Bioscience (SKYE) nimacimab for Obesity Subscribers Only Subscribers Only Subscribers Only
10/6/25 Biomea Fusion (BMEA) BMF-219 for Diabetes Mellitus, Type II Subscribers Only Subscribers Only Subscribers Only
9/29/25 Bristol Myers Squibb (BMY) Danicamtiv for Cardiomyopathy - Dilated Subscribers Only Subscribers Only Subscribers Only
9/29/25 Daiichi (4568) Enhertu for HER2+ Breast Cancer Subscribers Only Subscribers Only Subscribers Only
9/29/25 Enanta Pharmaceuticals (ENTA) EDP-938 for Respiratory Syncytial Virus (RSV) Treatment Subscribers Only Subscribers Only Subscribers Only

Upcoming Catalysts

More
Expected Date Range Lead Company Drug Expected Catalyst
06/25/2025 Subscribers Only Subscribers Only Company - Analyst/R&D Update
06/25/2025 Subscribers Only Subscribers Only Company - Analyst/R&D Update
06/26/2025 Subscribers Only Subscribers Only Company - Analyst/R&D Update
09/08/2025 Subscribers Only Subscribers Only Company - Analyst/R&D Update
09/17/2025 Subscribers Only Subscribers Only Company - Analyst/R&D Update